Report Sections

See All Reports

Coronavirus Infections (787) Severe Acute Respiratory Syndrome (538) Infection (447) Pneumonia (358) Communicable Diseases (191) Respiratory Distress Syndrome, Adult (179) Acute Lung Injury (142) Respiratory Distress Syndrome, Newborn (141) (127) Syndrome (123) Virus Diseases (88) Depression (78) Pneumonia, Viral (77) Critical Illness (67) Anxiety Disorders (49) Disease (40) Respiratory Tract Infections (38) Neoplasms (36) Stress Disorders, Post-Traumatic (36) Wounds and Injuries (35) Emergencies (34) Cardiovascular Diseases (33) Diabetes Mellitus (33) Inflammation (33) Stress Disorders, Traumatic (31) Stress, Psychological (30) Depressive Disorder (29) Lung Injury (29) Acute Kidney Injury (27) Respiratory Tract Diseases (27) Hypoxia (26) Mental Disorders (26) Thrombosis (25) Hypertension (24) Lung Diseases (24) Influenza, Human (22) Disease Progression (21) Olfaction Disorders (20) Arthritis (19) Respiration Disorders (19) Sclerosis (19) Burnout, Psychological (18) Diabetes Mellitus, Type 2 (18) Embolism (18) Fibrosis (18) Multiple Sclerosis (18) Thromboembolism (18) HIV Infections (16) Pulmonary Embolism (16) Respiratory Aspiration (16) Stroke (16) Blood Coagulation Disorders (15) Cognitive Dysfunction (15) Hemostatic Disorders (15) Pulmonary Disease, Chronic Obstructive (15) Pulmonary Fibrosis (15) Arthritis, Rheumatoid (14) Autism Spectrum Disorder (14) Chronic Disease (14) Heart Diseases (14) Kidney Diseases (14) Lung Diseases, Interstitial (14) Lung Diseases, Obstructive (14) Asthma (13) Brain Injuries (13) Chronic Pain (13) Myocardial Infarction (13) Substance-Related Disorders (13) Heart Failure (12) Lung Neoplasms (12) Venous Thrombosis (12) Autistic Disorder (11) Colitis (11) Colitis, Ulcerative (11) Crohn Disease (11) Dyspnea (11) Infarction (11) Obesity (11) Ulcer (11) Diabetes Mellitus, Type 1 (10) Pregnancy Complications (10) Rheumatic Diseases (10) Brain Injuries, Traumatic (9) Burnout, Professional (9) Coronary Artery Disease (9) Cystic Fibrosis (9) Depression, Postpartum (9) Feeding and Eating Disorders (9) Inflammatory Bowel Diseases (9) Liver Diseases (9) Myocarditis (9) Parkinson Disease (9) Pneumonia, Ventilator-Associated (9) Pulmonary Valve Insufficiency (9) Renal Insufficiency, Chronic (9) Respiratory Syncytial Virus Infections (9) Alzheimer Disease (8) Carcinoma (8) Collagen Diseases (8) Dementia (8) Frailty (8) Hematologic Neoplasms (8) Ischemia (8) Overweight (8) Problem Behavior (8) Psychotic Disorders (8) Sepsis (8) Venous Thromboembolism (8) Vitamin D Deficiency (8) Alcoholism (7) Convalescence (7) Coronary Disease (7) Infertility (7) Kidney Failure, Chronic (7) Musculoskeletal Pain (7) Myocardial Ischemia (7) Parasomnias (7) Spinal Cord Injuries (7) Acute Coronary Syndrome (6) Alcohol Drinking (6) Breast Neoplasms (6) Child Development Disorders, Pervasive (6) Deglutition Disorders (6) Dyssomnias (6) Fatigue (6) Immune System Diseases (6) Leukemia (6) Lupus Erythematosus, Systemic (6) Lymphoma (6) Lymphopenia (6) Neurologic Manifestations (6) Osteoarthritis (6) Pediatric Obesity (6) Psoriasis (6) RNA Virus Infections (6) Renal Insufficiency (6) Shock (6) Autoimmune Diseases (5) Brain Diseases (5) Bronchiectasis (5) Carcinoma, Non-Small-Cell Lung (5) Colorectal Neoplasms (5) Coronaviridae Infections (5) Delirium (5) Depressive Disorder, Major (5) Disease Susceptibility (5) Fibromyalgia (5) Gastroparesis (5) Hypersensitivity (5) Immunologic Deficiency Syndromes (5) Metabolic Syndrome (5) Mobility Limitation (5) Multiple Organ Failure (5) Neoplasm Metastasis (5) Nervous System Diseases (5) Occupational Stress (5) Osteoarthritis, Knee (5) (5) Premature Birth (5) Prostatic Neoplasms (5) Schizophrenia (5) Sleep Apnea Syndromes (5) Sleep Apnea, Obstructive (5) Toxemia (5) Triple Negative Breast Neoplasms (5) Acquired Immunodeficiency Syndrome (4) Adenoviridae Infections (4) Anemia, Sickle Cell (4) Appendicitis (4) Arthritis, Psoriatic (4) Atrial Fibrillation (4) Attention Deficit Disorder with Hyperactivity (4) Behavior, Addictive (4) Body Weight (4) Coinfection (4) Colonic Neoplasms (4) Cross Infection (4) Death (4) Dermatitis (4) Disseminated Intravascular Coagulation (4) Embolism and Thrombosis (4) Endometriosis (4) Head and Neck Neoplasms (4) Heart Arrest (4) Hemorrhage (4) Hypertension, Pulmonary (4) Intestinal Diseases (4) Liver Cirrhosis (4) Malnutrition (4) Metabolic Diseases (4) Migraine Disorders (4) Mycobacterium Infections (4) Pancreatic Neoplasms (4) Panic Disorder (4) Peripheral Arterial Disease (4) Postoperative Complications (4) Prediabetic State (4) Signs and Symptoms, Respiratory (4) Sjogren's Syndrome (4) Sleep Initiation and Maintenance Disorders (4) Systemic Inflammatory Response Syndrome (4) Thrombophilia (4) Tobacco Use Disorder (4) Vascular Diseases (4) Weight Loss (4) Amyotrophic Lateral Sclerosis (3) Arrhythmias, Cardiac (3) Asymptomatic Diseases (3) Carcinoma, Renal Cell (3) Cardiomyopathies (3) Celiac Disease (3) Cerebral Palsy (3) Chilblains (3) Common Cold (3) Dermatitis, Atopic (3) Developmental Disabilities (3) Digestive System Diseases (3) Dysgeusia (3) Eczema (3) Fatigue Syndrome, Chronic (3) Fever (3) Gastrointestinal Diseases (3) Giant Cell Arteritis (3) Glucose Intolerance (3) Glucose Metabolism Disorders (3) Headache (3) Heart Defects, Congenital (3) Hemophilia A (3) Huntington Disease (3) Hypothermia (3) Idiopathic Pulmonary Fibrosis (3) Leukemia, Lymphoid (3) Macular Edema (3) Measles (3) Melanoma (3) Motor Neuron Disease (3) Mouth Diseases (3) Mucocutaneous Lymph Node Syndrome (3) Multiple Sclerosis, Relapsing-Remitting (3) (3) Neuroendocrine Tumors (3) Obstetric Labor, Premature (3) Ovarian Neoplasms (3) Paramyxoviridae Infections (3) Peripheral Vascular Diseases (3) Polymyalgia Rheumatica (3) Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) Pregnancy Complications, Infectious (3) Psychological Trauma (3) Pulmonary Edema (3) Rare Diseases (3) Rheumatic Fever (3) ST Elevation Myocardial Infarction (3) Seizures (3) Sleep Wake Disorders (3) Spondylarthritis (3) Taste Disorders (3) Ventricular Dysfunction (3) Ventricular Dysfunction, Left (3) Acute Disease (2) Ageusia (2) Agoraphobia (2) Alopecia (2) Alpha 1-Antitrypsin Deficiency (2) Angina Pectoris (2) Anxiety, Separation (2) Apnea (2) Arteritis (2) Asymptomatic Infections (2) Atherosclerosis (2) Back Pain (2) Bacteremia (2) Bacterial Infections (2) Behcet Syndrome (2) Bipolar Disorder (2) Caliciviridae Infections (2) Cataract (2) Clinical Deterioration (2) Clostridium Infections (2) Cognition Disorders (2) Communicable Diseases, Emerging (2) Compassion Fatigue (2) Compulsive Personality Disorder (2) Congenital Abnormalities (2) Conjunctivitis (2) Diabetic Nephropathies (2) Diarrhea (2) Drug-Related Side Effects and Adverse Reactions (2) Emphysema (2) Endocarditis (2) Endocrine System Diseases (2) Eye Diseases (2) Fatty Liver (2) Fistula (2) Fractures, Stress (2) Ganglion Cysts (2) Gastroenteritis (2) Gastroesophageal Reflux (2) Glioblastoma (2) Gout (2) Healthcare-Associated Pneumonia (2) Heart Failure, Systolic (2) Hematologic Diseases (2) Hepatitis (2) Hepatitis A (2) Hepatitis C (2) Hyperglycemia (2) Hyperkinesis (2) Hyperphagia (2) Hypertension, Pregnancy-Induced (2) Hypotension (2) Hypoventilation (2) Intervertebral Disc Degeneration (2) Ischemic Attack, Transient (2) Jaundice (2) Joint Diseases (2) Leukemia, Myeloid, Acute (2) Liver Failure (2) Low Back Pain (2) Lymphedema (2) Lymphoproliferative Disorders (2) Macular Degeneration (2) Meningitis (2) Meningitis, Meningococcal (2) Mood Disorders (2) Multiple Myeloma (2) Muscle Spasticity (2) Muscular Dystrophies (2) Mutism (2) Mycoses (2) Myelodysplastic Syndromes (2) Myeloproliferative Disorders (2) Myofascial Pain Syndromes (2) Myositis (2) Necrosis (2) Neoplasms, Plasma Cell (2) Nerve Degeneration (2) Neurocognitive Disorders (2) Neurodevelopmental Disorders (2) Nidovirales Infections (2) Non-alcoholic Fatty Liver Disease (2) Noncommunicable Diseases (2) Nutrition Disorders (2) Obesity, Morbid (2) Obsessive-Compulsive Disorder (2) Oral Manifestations (2) Pain, Postoperative (2) Pancreatitis (2) Phobia, Social (2) Phobic Disorders (2) Pneumonia, Pneumocystis (2) Pre-Eclampsia (2) Pulmonary Eosinophilia (2) Purpura, Thrombocytopenic, Idiopathic (2) Recurrence (2) Respiratory Sounds (2) Rupture (2) Sarcoidosis (2) (2) Scleroderma, Systemic (2) Shock, Septic (2) Small Cell Lung Carcinoma (2) Spinal Diseases (2) Sprains and Strains (2) Stillbirth (2) Suicidal Ideation (2) Suicide (2) Tachycardia (2) Temporomandibular Joint Disorders (2) Temporomandibular Joint Dysfunction Syndrome (2) Thoracic Diseases (2) Thrombocytopenia (2) Trauma and Stressor Related Disorders (2) Tuberculosis (2) Urinary Bladder, Overactive (2) Urinary Tract Infections (2) Uterine Cervical Neoplasms (2) Uveitis (2) Vision Disorders (2) Vision, Low (2) Yellow Fever (2) Abruptio Placentae (1) Acalculous Cholecystitis (1) (1) Acute Lung Injur (1) Adenocarcinoma (1) Adjustment Disorders (1) Adrenal Insufficiency (1) Alcohol Drinking in College (1) Alcohol-Related Disorders (1) Alcoholic Intoxication (1) Altitude Sickness (1) Alveolitis, Extrinsic Allergic (1) Amblyopia (1) Anemia, Aplastic (1) Aneurysm (1) Aneurysm, Ruptured (1) Angina, Stable (1) Angioedema (1) Angioedemas, Hereditary (1) Anorexia (1) Anorexia Nervosa (1) Aortic Valve Stenosis (1) Arthritis, Juvenile (1) Aspergillosis (1) Aspergillosis, Allergic Bronchopulmonary (1) Asphyxia Neonatorum (1) Asthenopia (1) Atrioventricular Block (1) Atrophy (1) Autonomic Nervous System Diseases (1) Barotrauma (1) Biliary Tract Neoplasms (1) Birth Weight (1) Blister (1) Body Weight Changes (1) Bone Diseases, Metabolic (1) Bone Marrow Diseases (1) Bradycardia (1) Brain Concussion (1) Breast Cancer Lymphedema (1) Bronchial Diseases (1) Bronchiolitis (1) Bronchitis (1) Bronchitis, Chronic (1) Bronchopulmonary Dysplasia (1) Brucellosis (1) Bruxism (1) Bulimia (1) Calculi (1) Carcinoma, Hepatocellular (1) Carcinoma, Ovarian Epithelial (1) Carcinoma, Small Cell (1) Carcinoma, Squamou (1) Carcinoma, Squamous Cell (1) Cardiotoxicity (1) Cardiovascular Abnormalities (1) Cellulitis (1) Cerebral Hemorrhage (1) Cerebrovascular Disorders (1) Chest Pain (1) Chlamydia Infections (1) Cholangiocarcinoma (1) Cholangitis (1) Cholecystitis (1) Cholecystitis, Acute (1) Chorea (1) Chronic Traumatic Encephalopathy (1) Ciliary Motility Disorders (1) Colonic Diseases (1) (1) Communication Disorders (1) Compulsive Behavior (1) Consciousness Disorders (1) Constipation (1) Constriction, Pathologic (1) Conversion Disorder (1) (1) Coronary Restenosis (1) Coronary Stenosis (1) (1) Cough (1) Coxsackievirus Infections (1) Cryopyrin-Associated Periodic Syndromes (1) (1) Deafness (1) Death, Sudden, Cardiac (1) Dehydration (1) Dental Calculus (1) Dental Plaque (1) Depressive Disorder, Treatment-Resistant (1) DiGeorge Syndrome (1) Diabetic Foot (1) Diabetic Neuropathies (1) Digestive System Neoplasms (1) Diphtheria (1) Down Syndrome (1) Drug Overdose (1) Dyskinesias (1) Dyspareunia (1) Dysphonia (1) Eclampsia (1) Emergence Delirium (1) Encephalitis (1) Endophthalmitis (1) Endotoxemia (1) Enterocolitis, Pseudomembranous (1) Enuresis (1) Eosinophilic Esophagitis (1) Epilepsy (1) Esophageal Fistula (1) Esophageal and Gastric Varices (1) Esophagitis (1) Esophagitis, Peptic (1) Eye Infections (1) Fabry Disease (1) Facial Pain (1) Familial Mediterranean Fever (1) Femoral Neck Fractures (1) Fetal Growth Retardation (1) Fetal Membranes, Premature Rupture (1) Fever of Unknown Origin (1) Food Hypersensitivity (1) Foot Ulcer (1) Fractures, Closed (1) Gait Disorders, Neurologic (1) Gastrointestinal Stromal Tumors (1) Gaucher Disease (1) Genetic Diseases, Inborn (1) Genetic Predisposition to Disease (1) Gestational Weight Gain (1) Gingivitis, Necrotizing Ulcerative (1) Glomerulonephritis, IGA (1) Headache Disorders, Secondary (1) Hearing Loss (1) Hearing Loss, Conductive (1) Heart Block (1) Heart Failure, Diastolic (1) Heart Murmurs (1) Helminthiasis (1) Hematoma (1) Hematoma, Subdural (1) Hematoma, Subdural, Chronic (1) Hemoglobinopathies (1) Hepatitis B (1) Hepatitis, Alcoholic (1) Hereditary Autoinflammatory Diseases (1) Herpes Labialis (1) Herpes Zoster (1) Hoarseness (1) Hodgkin Disease (1) Hyaline Membrane Disease (1) Hyperaldosteronism (1) Hypercapnia (1) Hyperphosphatemia (1) Hyperplasia (1) Hypersensitivity, Immediate (1) Hypokalemia (1) Hyponatremia (1) Hypoparathyroidism (1) Iatrogenic Disease (1) (1) Infant, Newborn, Diseases (1) (1) Infec (1) Infect (1) Infecti (1) Infertility, Female (1) Infertility, Male (1) Intellectual Disability (1) Intermittent Claudication (1) Intestinal Atresia (1) Intracranial Aneurysm (1) Intracranial Hypertension (1) Intracranial Thrombosis (1) Jaundice, Obstructive (1) Keratoconjunctivitis (1) Keratosis (1) Keratosis, Actinic (1) Kidney Calculi (1) Language Disorders (1) Leishmaniasis (1) Leukemia, Lymphocytic, Chronic, B-Cell (1) Leukemia, Myeloid (1) Leukemia, Myelomonocytic, Acute (1) Leukemia, Myelomonocytic, Chronic (1) Liver Cirrhosis, Biliary (1) Lyme Disease (1) Lymphocytosis (1) Lymphoma, B-Cell (1) Lymphoma, Mantle-Cell (1) Macrophage Activation Syndrome (1) Malaria (1) Maternal Death (1) Maxillofacial Injuries (1) May-Thurner Syndrome (1) Memory Disorders (1) Meningococcal Infections (1) Menorrhagia (1) Menstruation Disturbances (1) Microvascular Rarefaction (1) Mitochondrial Diseases (1) Molluscum Contagiosum (1) Monoclonal Gammopathy of Undetermined Significance (1) Mouth, Edentulous (1) Movement Disorders (1) Mucositis (1) Multiple Chronic Conditions (1) Muscular Atrophy (1) Muscular Dystrophy, Duchenne (1) Myalgia (1) Myocardial Reperfusion Injury (1) Nasal Polyps (1) Needlestick Injuries (1) Neonatal Sepsis (1) Neoplastic Cells, Circulating (1) Nephritis (1) Neurobehavioral Manifestations (1) Neuromuscular Diseases (1) Neuromyelitis Optica (1) Obsessive Behavior (1) Olfactory Nerve Injuries (1) Orbital Cellulitis (1) Oropharyngeal Neoplasms (1) Osteoarthritis, Hip (1) Osteochondritis (1) Osteomyelitis (1) Otitis (1) Otitis Media (1) Otitis Media with Effusion (1) Overwei (1) Pain (1) Pain, Intractable (1) Pain, Procedural (1) Papillomavirus Infections (1) Paraproteinemias (1) Paresis (1) Peanut Hypersensitivity (1) Perinatal Death (1) Periodontal Diseases (1) Peripheral Nervous System Diseases (1) Peritoneal Neoplasms (1) Pharyngeal Diseases (1) Pneumon (1) Pneumonia, Bacterial (1) Polyps (1) Pregnancy in Diabetics (1) Preleukemia (1) Presbyopia (1) Primary Dysautonomias (1) Primary Myelofibrosis (1) Prostatic Hyperplasia (1) Protein Deficiency (1) Protein-Energy Malnutrition (1) Psychophysiologic Disorders (1) Puerperal Infection (1) Pulmonary Alveolar Proteinosis (1) Pulmonary Aspergillosis (1) Pulmonary Atelectasis (1) Rabies (1) Radiculopathy (1) Rectal Neoplasms (1) Reperfusion Injury (1) Respiratory Distress Syndrom (1) Respiratory Distress Syndrome, Newbor (1) Respiratory Hypersensitivity (1) Retinal Vein Occlusion (1) Sarcoidosis, Pulmonary (1) Sarcopenia (1) Schizophrenia Spectrum and Other Psychotic Disorders (1) Scleroderma, Localized (1) (1) Self-Injurious Behavior (1) Sexually Transmitted Diseases (1) Sexually Transmitted Diseases, Bacterial (1) Shock, Cardiogenic (1) Short Bowel Syndrome (1) Signs and Symptoms, Digestive (1) Skin Abnormalities (1) Skin Diseases (1) Skin Manifestations (1) Skin Neoplasms (1) Skull Fractures (1) Sleep Apnea, Central (1) Soft Tissue Neoplasms (1) Somatoform Disorders (1) Spinal Cord Diseases (1) Spinal Dysraphism (1) Spinal Stenosis (1) Spondylolisthesis (1) Status Epilepticus (1) Stomatitis (1) Stress Disorders (1) Stress Disorders, Traumatic, Acute (1) Subarachnoid Hemorrhage (1) Superinfection (1) Syncope (1) Syncope, Vasovagal (1) Tachycardia, Sinus (1) Tachycardia, Ventricular (1) Thalassemia (1) Thrombophlebitis (1) Thrombotic Microangiopathies (1) Torsades de Pointes (1) Tourette Syndrome (1) Trauma, Nervous System (1) Trichuriasis (1) Tuberculosis, Pulmonary (1) Urinary Bladder Neoplasms (1) Urinary Bladder, Underactive (1) Urinary Incontinence (1) Urinary Retention (1) Urogenital Neoplasms (1) Urologic Diseases (1) Urticaria (1) Uterine Neoplasms (1) Vaginal Neoplasms (1) Venous Insufficiency (1) Ventricular Dysfunction, Right (1) Virus (1) Voice Disorders (1) Von Willebrand Diseases (1) Vulvar Neoplasms (1) Weight Gain (1) Xerostomia (1) beta-Thalassemia (1)

D015212: Inflammatory Bowel Diseases

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Navigate: Clinical Trials and HPO

Correlated Drug Terms (10)

Name (Synonyms) Correlation
drug3877 TD-1473 [Tablet B] Wiki 0.33
drug844 Cannabis, Medical Wiki 0.33
drug3876 TD-1473 [Tablet A] Wiki 0.33
Name (Synonyms) Correlation
drug3008 Plasma from a volunteer donor Wiki 0.33
drug1248 Disulfiram Wiki 0.24
drug3429 SARS-CoV-2 convalescent plasma Wiki 0.19
drug1993 Interview Wiki 0.19
drug492 BNT162b1 Wiki 0.19
drug1265 Doxycycline Wiki 0.15
drug2916 Placebo Wiki 0.04

Correlated MeSH Terms (28)

Name (Synonyms) Correlation
D007410 Intestinal Diseases NIH 0.67
D000070627 Chronic Traumatic Encephalopathy NIH 0.33
D005879 Tourette Syndrome NIH 0.33
Name (Synonyms) Correlation
D001714 Bipolar Disorder NIH 0.24
D003092 Colitis NIH 0.20
D003093 Colitis, Ulcerative NIH 0.20
D003424 Crohn Disease NIH 0.20
D000690 Amyotrophic Lateral Sclerosis NIH 0.19
D012640 Seizures NIH 0.19
D016472 Motor Neuron Disease NIH 0.19
D000755 Anemia, Sickle Cell NIH 0.17
D005356 Fibromyalgia NIH 0.15
D001927 Brain Diseases NIH 0.15
D000070642 Brain Injuries, Traumatic NIH 0.11
D010300 Parkinsonian NIH 0.11
D001930 Brain Injuries, NIH 0.09
D059350 Chronic Pain NIH 0.09
D009103 Multiple Sclerosis NIH 0.08
D012598 Scoliosi NIH 0.08
D040921 Stress Disorders, Traumatic NIH 0.06
D014947 Wounds and Injuries NIH 0.06
D013313 Stress Disorders, Post-Traumatic NIH 0.06
D004194 Disease NIH 0.05
D013577 Syndrome NIH 0.03
D045169 Severe Acute Respiratory Syndrome NIH 0.03
D003141 Communicable Diseases NIH 0.02
D018352 Coronavirus Infections NIH 0.02
D007239 Infection NIH 0.02

Correlated HPO Terms (11)

Name (Synonyms) Correlation
HP:0002037 Inflammation of the large intestine HPO 1.00
HP:0002242 Abnormal intestine morphology HPO 0.67
HP:0100754 Mania HPO 0.24
Name (Synonyms) Correlation
HP:0002583 Colitis HPO 0.20
HP:0100279 Ulcerative colitis HPO 0.20
HP:0100280 Crohn's disease HPO 0.20
HP:0006802 Abnormal anterior horn cell morphology HPO 0.19
HP:0007354 Amyotrophic lateral sclerosis HPO 0.19
HP:0001250 Seizure HPO 0.17
HP:0001298 Encephalopathy HPO 0.15
HP:0012532 Chronic pain HPO 0.09

Clinical Trials

Navigate: Correlations   HPO

There are 9 clinical trials

1 Assessing the Drug Exposure Risk of Infants Breastfed by Women With Inflammatory Bowel Disease

Breastfeeding is beneficial to both mother and baby. However, many breastfeeding women are affected by long-term health conditions and need to take medications. Sometimes, concerns about transfer of drugs to infants via breast milk lead the mothers to either avoid breastfeeding or stop their medication. Inflammatory Bowel Disease (IBD) is a chronic condition that is marked by an abnormal response of the body's immune system, and high levels of certain proteins that cause inflammation (Cytokines like Tumor Necrosis Factor-alpha or TNFα). A group of drugs called "biologics" target and stop these proteins from causing inflammation, and have been successfully used to treat this condition. Inflammatory proteins may be present in breast milk of healthy women in variable levels, and may play a role in development of infant's brain and immune system. This study is being conducted to investigate: - Concentration of some of the inflammatory proteins in breast milk of mothers with IBD and healthy controls - Interaction between these proteins and biologics in breast milk of women with IBD - Potential role of these proteins (and their interaction with biologics) on development of infant learning and memory function It has been presumed that concentrations of TNFα and some other cytokines are higher in breast milk of women with IBD, and the biologics can normalize these high levels. Due to precautions for COVID-19, the study now consists of only two mandatory study visits and two optional study visits. The mandatory visits include two home visits in the first 4 months postpartum to complete a participant questionnaire and collect a small sample of breast milk at each visit. The optional study visits consist of two visits at the Hospital for Sick Children for evaluation of learning and memory function of the infant at the ages of 12 and 18 months. Additionally, mothers will be required to complete for their infant subscales of The Ages and Stages Questionnaires®, Third Edition (ASQ®-3) either in person or over the telephone at the ages of 12 months and 18 months.

  1. Crohn's Disease
  2. Ulcerative Colitis
  3. Healthy Controls
MeSH:Crohn Disease Colitis Colitis, Ulcerative Intestinal Diseases Inflammatory Bowel Diseases
HPO:Abnormal intestine morphology Colitis Crohn's disease Inflammation of the large intestine Ulcerative colitis

Primary Outcomes

Description: Multiplex assay will be used to measure TNFα and downstream chemokines including CCL2, CCL4, CCL7, CXCL10 in breast milk of two groups of participants (women with IBD and healthy controls). (The unit of measurement is the same for all these cytokines)

Measure: Levels of TNFα and its downstream chemokines (CCL2, CCL4, CCL7, and CXCL10) in breast milk of women with IBD and healthy controls by Multiplex assay

Time: 4 years

Secondary Outcomes

Description: ELISA assay will be used to measure total and free drug levels (bound and unbound to TNFα) in breast milk of lactating women with IBD. (The unit of measurement is the same for infliximab and adalimumab).

Measure: Milk concentration of TNFα inhibitors (infliximab, adalimumab) at different time-points between two doses of medication, in lactating women with IBD by ELISA assay

Time: 4 years

Description: The infants of women with IBD and healthy controls will be examined for cognitive development using Bayley-III

Measure: Scores on cognitive subset of Bayley Scales of Infant and Toddler development- Third Version (Bayley-III) in infants of healthy controls and women with IBD

Time: 4 years

Description: Infants of healthy controls and women with IBD will be examined for communication and problem-solving development using the ASQ®-3. This supplementary measure is intended to provide additional data as an alternative to Bayley test under unprecedented circumstances which preclude participants to complete Bayley test at the Hospital for Sick Children

Measure: Scores on the "Problem-solving" and "Communication" subscales of The Ages and Stages Questionnaire (ASQ®-3) in infants of healthy controls and women with IBD

Time: 4 years

Description: An estimation of the population distribution of anti-TNFα antibodies (infliximab and adalimumab) in breast milk of women with IBD will be made, using population pharmacokinetic modelling

Measure: Simulated/predicted profiles of TNFα inhibitors (infliximab, adalimumab) in breast milk in a large population of lactating women with IBD by population pharmacokinetic modelling

Time: 4 years
2 Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19

This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.

  1. Chronic Pain
  2. Chronic Pain Syndrome
  3. Chronic Pain Due to Injury
  4. Chronic Pain Due to Trauma
  5. Fibromyalgia
  6. Seizures
  7. Hepatitis C
  8. Cancer
  9. Crohn Disease
  10. HIV/AIDS
  11. Multiple Sclerosis
  12. Traumatic Brain Injury
  13. Sickle Cell Disease
  14. Post Traumatic Stress Disorder
  15. Tourette Syndrome
  16. Ulcerative Colitis
  17. Glaucoma
  18. Epilepsy
  19. Inflammatory Bowel Diseases
  20. Parkinson Disease
  21. Amyotrophic Lateral Sclerosis
  22. Chronic Traumatic Encephalopathy
  23. Anxiety
  24. Depression
  25. Insomnia
  26. Autism
  27. Opioid-use Disorder
  28. Bipolar Disorder
  29. Covid19
  30. SARS-CoV Infection
  31. COVID-19
  32. Corona Virus Infection
  33. Coronavirus
  1. Drug: Cannabis, Medical
MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Fibromyalgia Crohn Disease Inflammatory Bowel Diseases Parkinson Disease Multiple Sclerosis Brain Injuries Brain Injuries, Traumatic Seizures Motor Neuron Disease Amyotrophic Lateral Sclerosis Brain Diseases Tourette Syndrome Chronic Traumatic Encephalopathy Anemia, Sickle Cell Disease Syndrome Sclerosis Chronic Pain Wounds and Injuries Stress Disorders, Traumatic Bipolar Disorder Stress Disorders, Post-Traumatic
HPO:Abnormal anterior horn cell morphology Amyotrophic lateral sclerosis Bilateral tonic-clonic seizure Bipolar affective disorder Chronic pain Crohn's disease Encephalopathy Focal-onset seizure Generalized-onset seizure Inflammation of the large intestine Mania Seizure

Primary Outcomes

Description: Covid-19 infection rates in cannabis users will be compared to rates in the general population. Our online questionnaire responses will compare infection rates of cannabis users in this study against the Johns Hopkins University Coronavirus Research Center data (

Measure: Prevention of COVID-19

Time: Five years

Description: Severity of persistent symptoms in cannabis users testing positive for active infection and/or antibodies will also be compared to the general population. Patients will answer the widely used FLU-PRO questionnaire, which asks about flu symptoms and severity, to capture diagnoses, symptoms, and medical interventions related to COVID-19. The data from cannabis user patients will be compared with national and international data surveys, such as the Covid Symptom Study (

Measure: Treatment of COVID-19

Time: Five years

Description: The primary objective is to assess the efficacy and safety of medical cannabis as medicine for treatment of chronic pain and other chronic debilitating diseases. Pain will be measured by Brief Pain Inventory (BPI) numeric scale. Change from baseline in BPI will be assessed at 3-month intervals. For prospective associations between cannabis use and outcomes, use of a lagged mixed-effects models will examine temporal associations between cannabis use and pain severity, opioid sparing, and patient satisfaction. Data will be analyzed from baseline and the annual follow-up waves.

Measure: Treatment of Symptoms

Time: Five years

Secondary Outcomes

Description: Secondary objectives include evaluating increases or decreases in quality of life, and increases or decreases in concomitant opioid use. Satisfaction with treatment will be measured by a Visual Analog Score (VAS). Change From baseline in Satisfaction with treatment measured by (VAS) be assessed at 3-month intervals.

Measure: Cannabis Impact on Quality of Life

Time: Five years

Description: Tertiary objectives will examine preferences for routes of administration, and preferences for THC / CBD ratios. Categorical factors will be summarized using frequencies and percentages, while continuous measure distributions will be described using means, standard deviations, and quartiles of interest.

Measure: Cannabis Route and Dosing

Time: Five years

Description: Incidence of Treatment-Related Adverse Events will be measured by Physician Global Assessment (PGA) numeric scale. Number of participants with Treatment-Related Adverse Events will be assessed by CTCAE v4.0.

Measure: Monitoring Adverse Events

Time: Five years
3 Prospective Multicenter Cohort of Patients With Inflammatory Bowel Disease Treated by Infliximab or Vedolizumab During COVID-19 Pandemic

Multicenter cohort of patients followed for 6 months during the pandemic in France with biocollection of sera and peripheral blood mononuclear cells

  1. IBD
  2. COVID
MeSH:Inflammatory Bowel Diseases
HPO:Inflammation of the large intestine

Primary Outcomes

Description: Impact of antibodies du to immunosuppressive protocol on the risk of viral infection

Measure: IgG and IgM anti SARS-CoV-2

Time: through study completion, an average of 2 year

Secondary Outcomes

Description: Describe clinical factors of the population of IBD patients treated with vedolizumab or infliximab who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management. weight (Kg) height (m) ABO Group ....

Measure: Clinical factors and severity of COVID-19 infection

Time: through study completion, an average of 2 year

Description: Describe demographic factors of the population of IBD patients treated with vedolizumab or infliximab who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management. ACCOMMODATION HOUSING AREA number of people at home ....

Measure: demographic factors and severity of COVID-19 infection

Time: through study completion, an average of 2 year

Description: Describe residual rates of treatments (edolizumab or infliximab) of the population of IBD patients who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management.

Measure: pharmacologic factors and severity of COVID-19 infection

Time: through study completion, an average of 2 year
4 The Effect of Patient's Perceptions for COVID-19 on the Inflammatory Bowel Disease-related Healthcare Utilization in the Hyperepidemic Area

The rapid spread of COVID-19 is expected to have a significant impact on medicine as well as all sectors worldwide. In particular, inflammatory bowel disease (IBD) is a chronic immune disease in which remission and activation are repeated and must be treated consistently throughout life. In addition, patients with IBD may be vulnerable to various infectious diseases due to the immuno-compromised state due to the use of immuno-suppressants or biological agents. During a pandemic, patients with IBD may postpone hospital visits due to concerns about infection with COVID-19, and if they cannot continue drug treatment, there is a concern about the flare up IBD disease activity. Therefore, in this study, we would like to investigate the current status of hospital utilization of IBD patients in Daegu, the epidemic area of COVID-19, and to investigate the effect of patient perception of COVID-19 on hospital ultilization.

  1. COVID-19
  2. Perception, Self
  3. Facilities and Services Utilization
  1. Other: Interview
MeSH:Inflammatory Bowel Diseases
HPO:Inflammation of the large intestine

Primary Outcomes

Description: Correlation between patient's perception of COVID-19 and medical use patterns during the pandemic period

Measure: Patient's perception of COVID-19 and medical use patterns

Time: 1day

Secondary Outcomes

Description: Exacerbation of symptoms in patients with IBD during the pandemic period

Measure: Exacerbation of symptoms

Time: 1day
5 PREPARE-IBD: Physician Responses to Disease Flares and Patient Adaptation in Relation to Events in Inflammatory Bowel Disease During COVID-19 Pandemic

To find out what adaptations have been made by Inflammatory bowel disease physicians and patients in relation to therapies in flaring IBD patients during severe acute respiratory syndrome 2-COV and what the impact of these is on IBD patients with no symptomatic COVID-19 and in suspected/confirmed COVID-19. Also whether there any IBD related factors impacting the outcome of patients with COVID-19 symptoms or COVID-19 disease

  1. Inflammatory Bowel Diseases
  2. Coronavirus Infection
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Intestinal Diseases Inflammatory Bowel Diseases
HPO:Abnormal intestine morphology Inflammation of the large intestine

Primary Outcomes

Measure: Flare of IBD needing change in therapy or surgery

Time: 3 months
6 PROTECT-ASUC: Covid-19 Pandemic Response Of assessmenT, EndosCopy and Treatment in Acute Severe Ulcerative Colitis: A Multi-centre Observational Case- Control Study

Whether the perceived changes in management of Acute Severe Ulcerative Colitis during the COVID pandemic are widespread, and whether they have any impact on patient outcomes

  1. Inflammatory Bowel Diseases
  2. COVID
MeSH:Colitis Colitis, Ulcerative Inflammatory Bowel Diseases
HPO:Colitis Inflammation of the large intestine Ulcerative colitis

Primary Outcomes

Description: The need for in-hospital colectomy or rescue therapy

Measure: Primary outcome measure: The need for in-hospital colectomy or rescue therapy

Time: 3 months

Secondary Outcomes

Description: Duration and type/route of steroid use

Measure: 2.1: Duration and type/route of steroid use

Time: 3 months

Description: 30 day colectomy free survival rates

Measure: 2.2: 30 day colectomy free survival rates

Time: 3 months

Description: Covid-19 infection rates

Measure: 2.3: Covid-19 infection rates

Time: 3 months

Description: Rate of Rescue therapy use

Measure: 2.4: Rate of Rescue therapy use

Time: 3 months

Description: Duration of hospital stay

Measure: 2.5: Duration of hospital stay

Time: 3 months

Description: Admission severity scoring

Measure: 2.6: Admission severity scoring

Time: 3 months

Description: Readmission rates

Measure: 2.7: Readmission rates

Time: 3 months
7 Impact of Isolation in Patients With IBD During the 2020 COVID-19 Crisis: a Mixed Methods Study

The coronavirus pandemic has changed healthcare dramatically in a short time. Individuals with chronic illnesses and services for them have had to adapt and change to deal with requirements for shielding and social isolation to reduce infection risk and management of medication investigation and ongoing review. It is increasingly recognised that the pandemic and the changes to daily life will have had a series of impacts on patients and health care services, including impacts on patients psychological well-being and the opportunity to seek medical care for non-CoViD illness. Psychological symptoms such as depression, anxiety and hopelessness is well described in adults and young people with inflammatory bowel disease. Quarantine has also been associated with these psychological symptoms and also post-traumatic stress. It is important to identify the extent of and factors that influence negative psychological consequences of isolation in patients with inflammatory bowel disease. This study will aim to assess what impact the isolation of patients during social isolation had in terms of psychological well-being - and what are the factors affecting this impact, particularly in younger and old age groups.

  1. Inflammatory Bowel Diseases
MeSH:Inflammatory Bowel Diseases
HPO:Inflammation of the large intestine

Primary Outcomes

Description: Psychological morbidity will be assessed through the 4 questionnaires

Measure: What impact has the isolation of patients during social isolation had in terms of psychological morbidity?

Time: Changes in psychological morbidity at 12 months

Secondary Outcomes

Description: psychological morbidity will be assessed via comparison of questionnaires from affiliated study against the time points of this study

Measure: Have levels of psychological morbidity in young people changed from levels prior to the CoViD pandemic?

Time: Changes in psychological morbidity at 12 months
8 SARS-CoV-2 Infection in Patients From Two Tertiary Inflammatory Bowel Disease (IBD) Centres: Frequency of Suspected and Confirmed Infections, Severity and Outcome Management

Most of the inflammatory bowel disease (IBD: Crohn's disease and ulcerative colitis) in a tertiary expert Centre are on immunosuppressive and/or biological therapy. Theoretically, these treatments may increase patients' risk of infection, in particular viral infection. Therefore, the current SARS-Cov-2 pandemia, with its unprecedent worldwide morbidity and mortality, may have a negative impact on IBD patients' clinical course. Identifying an increased risk in this particular patients' population as well as the risk/protective factors is of outstanding importance, in order to adapt their treatment and surveillance. As a consequence, our aims were (i) to measure retrospectively the risk of SARS-CoV-2 (proven by biological testing or suspected due to record of potential clinical symptoms of COVID-19 infection) in this patients' cohort (principal objective), (ii) to identify risk or protective factors for SARS-CoV-2 infection in IBD, and (iii) to analyze the outcome of patients in case of suspected or confirmed COVID-19. The results of this study may be important to adjust our surveillance and therapeutic strategy in these patients, in particular if high virus circulation will occur in the future.

  1. Inflammatory Bowel Disease
MeSH:Intestinal Diseases Inflammatory Bowel Diseases
HPO:Abnormal intestine morphology Inflammation of the large intestine

Primary Outcomes

Measure: Retrospective analysis of severity and specific needs in case of SARS-CoV-2 infection in IBD patients

Time: Files analysed retrospectily from March 1st, 2020 to July 31, 2020 will be examined
9 A Phase 1, Two-Part, Open-Label Study to Assess the Relative Bioavailability of Two TD-1473 Tablet Formulations Under Fasted and Fed Conditions in Healthy Subjects and the Pharmacokinetics of TD-1473 in Healthy Chinese Subjects

This is a Phase 1, 2-part, open-label study. Part A will be a formulation bridging and food effect study in healthy adult subjects. Part B will be an assessment of pharmacokinetics (PK) in healthy adult Chinese subjects.

  1. Intestinal Disorder
  2. Bowel Diseases, Inflammatory
  1. Drug: TD-1473 [Tablet A]
  2. Drug: TD-1473 [Tablet B]
MeSH:Intestinal Diseases Inflammatory Bowel Diseases
HPO:Abnormal intestine morphology Inflammation of the large intestine

Primary Outcomes

Description: Area under the concentration-time curve, from time 0 to the last observed non-zero concentration (AUC0-t) of TD-1473 in Plasma

Measure: AUC0-t

Time: Predose and at prespecified time points up to 5 days after dosing on Day 1 of each period

Description: Area under the concentration-time curve, from time 0 extrapolated to infinity (AUC0-inf) of TD-1473 in Plasma

Measure: AUC0-inf

Time: Predose and at prespecified time points up to 5 days after dosing on Day 1 of each period

Description: Maximum observed concentration (Cmax) of TD-1473 in Plasma

Measure: Cmax

Time: Predose and at prespecified time points up to 5 days after dosing on Day 1 of each period

Secondary Outcomes

Description: Number and severity of treatment emergent adverse events.

Measure: Adverse events

Time: Day 1 through Day 7 of each period

HPO Nodes


Data processed on September 26, 2020.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports   MeSH Reports   HPO Reports  


4,180 reports on interventions/drugs


691 reports on MeSH terms


263 reports on HPO terms

All Terms

Alphabetical index of all Terms

Google Colab

Python example via Google Colab Notebook